

Shahin Akhondzadeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3485824/publications.pdf>

Version: 2024-02-01

353
papers

11,974
citations

20817

60
h-index

40979

93
g-index

357
all docs

357
docs citations

357
times ranked

11056
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. <i>Depression and Anxiety</i> , 2009, 26, 607-611.	4.1	328
2	Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. <i>Journal of Affective Disorders</i> , 2012, 141, 308-314.	4.1	280
3	Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 90, 179-185.	2.0	275
4	Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 53-59.	1.5	248
5	Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. <i>Phytotherapy Research</i> , 2005, 19, 148-151.	5.8	231
6	Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. <i>Journal of Ethnopharmacology</i> , 2005, 97, 281-284.	4.1	230
7	Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]. <i>BMC Complementary and Alternative Medicine</i> , 2004, 4, 12.	3.7	217
8	A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. <i>Psychopharmacology</i> , 2010, 207, 637-643.	3.1	202
9	Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 863-866.	1.9	196
10	Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 363-367.	1.5	190
11	ORIGINAL ARTICLE: Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 581-588.	1.5	190
12	Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. <i>Phytomedicine</i> , 2006, 13, 607-611.	5.3	184
13	Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 439-442.	4.8	175
14	Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]. <i>BMC Psychiatry</i> , 2004, 4, 9.	2.6	158
15	Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 515-519.	2.3	150
16	Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. <i>Journal of Ethnopharmacology</i> , 2005, 102, 202-207.	4.1	147
17	Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2006, 84, 405-410.	2.0	142
18	Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2012, 37, 2093-2100.	5.4	126

#	ARTICLE	IF	CITATIONS
19	Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1007-1012.	4.8	124
20	Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 175-180.	3.1	123
21	N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia. <i>Clinical Neuropharmacology</i> , 2013, 36, 185-192.	0.7	121
22	Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. <i>Human Psychopharmacology</i> , 2014, 29, 351-359.	1.5	114
23	Glutathione-Related Factors and Oxidative Stress in Autism, A Review. <i>Current Medicinal Chemistry</i> , 2012, 19, 4000-4005.	2.4	111
24	A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. <i>Journal of Affective Disorders</i> , 2014, 155, 216-222.	4.1	111
25	Herbal medicine in the treatment of Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 113-118.	1.9	109
26	Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2013, 225, 51-59.	3.1	109
27	Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 123-127.	4.8	103
28	Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. <i>Psychoneuroendocrinology</i> , 2013, 38, 767-776.	2.7	101
29	Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1269-1272.	4.8	99
30	Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia. <i>CNS Drugs</i> , 2013, 27, 57-65.	5.9	99
31	Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 783-789.	2.1	98
32	Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 131-137.	1.5	96
33	Saffron: The Golden Spice with Therapeutic Properties on Digestive Diseases. <i>Nutrients</i> , 2019, 11, 943.	4.1	96
34	Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. <i>Human Psychopharmacology</i> , 2013, 28, 54-60.	1.5	95
35	Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. <i>Psychopharmacology</i> , 2012, 223, 381-388.	3.1	94
36	PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Depression and Anxiety</i> , 2015, 32, 167-173.	4.1	94

#	ARTICLE	IF	CITATIONS
37	Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. <i>Schizophrenia Research</i> , 2009, 107, 206-212.	2.0	93
38	Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Psychiatry Research</i> , 2014, 215, 540-546.	3.3	87
39	N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism. <i>Clinical Neuropharmacology</i> , 2015, 38, 11-17.	0.7	86
40	Comparing Effects of Ketamine and Thiopental Administration During Electroconvulsive Therapy in Patients With Major Depressive Disorder. <i>Journal of ECT</i> , 2014, 30, 15-21.	0.6	85
41	Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 253-259.	4.8	83
42	Next generation sequencing: implications in personalized medicine and pharmacogenomics. <i>Molecular BioSystems</i> , 2016, 12, 1818-1830.	2.9	82
43	Prevalence of obsessive-compulsive disorder in Iran. <i>BMC Psychiatry</i> , 2004, 4, 2.	2.6	81
44	Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1428-1433.	2.2	81
45	Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 32-36.	4.8	80
46	Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. <i>Journal of Affective Disorders</i> , 2011, 129, 327-331.	4.1	80
47	N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 214-219.	1.5	80
48	Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. <i>Bipolar Disorders</i> , 2015, 17, 606-614.	1.9	78
49	Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. <i>Bipolar Disorders</i> , 2006, 8, 485-489.	1.9	75
50	Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 369-373.	1.5	74
51	Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. <i>Journal of Affective Disorders</i> , 2016, 204, 1-8.	4.1	70
52	Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 347-353.	1.5	70
53	A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. <i>Psychiatry Research</i> , 2009, 168, 234-237.	3.3	69
54	Ginkgo biloba for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 76-80.	4.8	66

#	ARTICLE	IF	CITATIONS
55	Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 369-374.	1.5	65
56	The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. <i>Schizophrenia Research</i> , 2010, 116, 101-106.	2.0	65
57	Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. <i>Pharmacopsychiatry</i> , 2017, 50, 152-160.	3.3	65
58	Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 145-149.	4.8	64
59	Effect of ritanserin, a 5HT _{2A/2C} antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1879-1883.	4.8	64
60	Mental Health Survey of the Iranian Adult Population in 2015. <i>Archives of Iranian Medicine</i> , 2017, 20, 128-134.	0.6	64
61	Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. <i>Quality of Life Research</i> , 2011, 20, 31-36.	3.1	62
62	Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 677-685.	4.0	62
63	Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 575-581.	4.0	60
64	Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients. <i>International Clinical Psychopharmacology</i> , 2016, 31, 20-26.	1.7	60
65	Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder. <i>CNS Drugs</i> , 2012, 26, 883-892.	5.9	58
66	Hippocampal synaptic plasticity and cognition. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 241-248.	1.5	57
67	Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 841-845.	4.8	57
68	Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. <i>Journal of Affective Disorders</i> , 2018, 235, 236-241.	4.1	55
69	A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. <i>Psychiatry Research</i> , 2015, 229, 181-187.	3.3	53
70	A Double-blind Placebo Controlled Trial of Piracetam Added to Risperidone in Patients with Autistic Disorder. <i>Child Psychiatry and Human Development</i> , 2008, 39, 237-245.	1.9	51
71	Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. <i>Pharmacopsychiatry</i> , 2015, 48, 136-140.	3.3	51
72	Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. <i>Journal of Affective Disorders</i> , 2015, 183, 149-155.	4.1	50

#	ARTICLE	IF	CITATIONS
73	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	2.6	49
74	Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 336-342.	1.4	48
75	The role of phthalate esters in autism development: A systematic review. <i>Environmental Research</i> , 2016, 151, 493-504.	7.5	48
76	Efficacy of <i>Crocus sativus</i> (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 717-724.	1.7	48
77	The effect of saffron (<i>Crocus sativus</i> L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial. <i>Journal of Research in Medical Sciences</i> , 2018, 23, 16.	0.9	48
78	Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. <i>Depression and Anxiety</i> , 2011, 28, 297-302.	4.1	47
79	Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial. <i>Paediatric Drugs</i> , 2013, 15, 505-514.	3.1	47
80	Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 650-656.	1.9	47
81	Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. <i>Pharmacopsychiatry</i> , 2017, 50, 64-68.	3.3	47
82	Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: <sc>A</sc> placebo-controlled, double-blind, randomized trial. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 517-526.	1.8	46
83	Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2018, 232, 127-133.	4.1	46
84	Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: <sc>R</sc> randomized, double-blind, placebo-controlled study. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 332-341.	1.8	45
85	Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism. <i>Clinical Neuropharmacology</i> , 2013, 36, 179-184.	0.7	44
86	Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2016, 75, 24-30.	3.1	44
87	The Role of Lead Exposure on Attention-Deficit/ Hyperactivity Disorder in Children: A Systematic Review. <i>Iranian Journal of Psychiatry</i> , 2016, 11, 1-14.	0.7	44
88	Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 195-201.	2.8	43
89	The effects of alcoholic extract of saffron (<i>Crocus sativus</i> L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial. <i>Complementary Therapies in Medicine</i> , 2018, 41, 196-202.	2.7	43
90	Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. <i>Iranian Journal of Psychiatry</i> , 2012, 7, 87-92.	0.7	43

#	ARTICLE	IF	CITATIONS
91	Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 344-350.	1.7	42
92	The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. <i>Human Psychopharmacology</i> , 2016, 31, 103-112.	1.5	41
93	Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 145-150.	1.5	40
94	Allopurinol as Adjunctive Therapy in Intractable Epilepsy: A Double-blind and Placebo-controlled Trial. <i>Archives of Medical Research</i> , 2007, 38, 313-316.	3.3	40
95	A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1810-1815.	4.8	40
96	Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. <i>Psychopharmacology</i> , 2011, 213, 809-815.	3.1	40
97	Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 55.	2.0	37
98	Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 784-791.	1.3	37
99	A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. <i>Psychopharmacology</i> , 2013, 228, 595-602.	3.1	36
100	Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 953-961.	1.9	36
101	Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2015, 23, 2.	2.0	36
102	Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. <i>Psychiatry Research</i> , 2017, 255, 59-65.	3.3	35
103	Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. <i>BMC Neurology</i> , 2004, 4, 12.	1.8	34
104	A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders. <i>Child Psychiatry and Human Development</i> , 2012, 43, 674-682.	1.9	34
105	A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 533-542.	3.1	34
106	Is transcranial direct current stimulation an effective modality in reducing food craving? A systematic review and meta-analysis. <i>Nutritional Neuroscience</i> , 2020, 23, 55-67.	3.1	34
107	Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. <i>Human Psychopharmacology</i> , 2012, 27, 411-418.	1.5	33
108	Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial. <i>Psychiatry Research</i> , 2014, 219, 431-435.	3.3	33

#	ARTICLE	IF	CITATIONS
109	A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 494-500.	1.3	32
110	Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 440-444.	1.3	32
111	Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 44-50.	1.5	32
112	Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. <i>Human Psychopharmacology</i> , 2008, 23, 79-86.	1.5	31
113	L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. <i>Journal of Psychiatric Research</i> , 2014, 59, 125-131.	3.1	30
114	Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2018, 103, 104-111.	3.1	30
115	Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 67-71.	1.5	30
116	Crocus Sativus L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders: a double-blind, randomized intervention study. <i>Psychiatry Research</i> , 2019, 282, 112613.	3.3	29
117	Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 398-405.	1.8	29
118	The Reliability and Validity of the Persian Version of Three-Factor Eating Questionnaire-R18 (TFEQ-R18) in Overweight and Obese Females. <i>Iranian Journal of Psychiatry</i> , 2017, 12, 100-108.	0.7	29
119	Interaction between adenosine and GABAA receptors on hippocampal neurones. <i>Brain Research</i> , 1994, 665, 229-236.	2.2	28
120	Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 49-52.	1.5	28
121	The effect of saffron (Crocus sativus L.) hydro-alcoholic extract on liver and renal functions in type 2 diabetic patients: A double-blinded randomized and placebo control trial. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2017, 9, 6-11.	1.7	28
122	Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. <i>Human Psychopharmacology</i> , 2010, 25, 530-535.	1.5	27
123	Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. <i>Clinical Nutrition ESPEN</i> , 2018, 25, 37-43.	1.2	27
124	Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 324-334.	1.5	27
125	Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial. <i>Child Psychiatry and Human Development</i> , 2011, 42, 367-375.	1.9	26
126	Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 205-212.	1.3	26

#	ARTICLE	IF	CITATIONS
127	A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 726-732.	4.8	25
128	A Double-Blind, Randomized, and Placebo-Controlled Trial of Buspirone Added to Risperidone in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 678-682.	1.4	25
129	Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. <i>Human Psychopharmacology</i> , 2010, 25, 560-565.	1.5	25
130	Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 472-478.	3.1	25
131	L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. <i>Human Psychopharmacology</i> , 2017, 32, e2584.	1.5	25
132	Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 361-368.	2.1	25
133	Avicenna and evidence based medicine. <i>Avicenna Journal of Medical Biotechnology</i> , 2014, 6, 1-2.	0.3	25
134	Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. <i>Acta Medica Iranica</i> , 2014, 52, 734-9.	0.8	25
135	Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 441-446.	1.5	24
136	Simvastatin adjunct therapy for negative symptoms of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 87-94.	1.7	24
137	Role of Melatonin in Body Weight: A Systematic Review and Meta-Analysis. <i>Current Pharmaceutical Design</i> , 2017, 23, 3445-3452.	1.9	24
138	Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial. <i>Journal of Affective Disorders</i> , 2014, 166, 201-205.	4.1	23
139	Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 513-519.	1.3	23
140	Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Neuropharmacology</i> , 2017, 40, 1-5.	0.7	23
141	<i>Passiflora incarnata</i> in the treatment of attention-deficit hyperactivity disorder in children and adolescents. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 609-614.	0.2	22
142	Saffron, Passionflower, Valerian and Sage for Mental Health. <i>Psychiatric Clinics of North America</i> , 2013, 36, 85-91.	1.3	22
143	Effect of omega-3 and ascorbic acid on inflammation markers in depressed shift workers in Shahid Tondgoyan Oil Refinery, Iran: a randomized double-blind placebo-controlled study. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 53, 36-40.	1.4	22
144	L-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 74-81.	1.3	22

#	ARTICLE	IF	CITATIONS
145	Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. <i>Physiology and Behavior</i> , 2018, 195, 151-157.	2.1	22
146	Nutrients for Prevention and Treatment of Mental Health Disorders. <i>Psychiatric Clinics of North America</i> , 2013, 36, 25-36.	1.3	21
147	Cardiovascular considerations in antidepressant therapy: an evidence-based review. <i>The Journal of Tehran Heart Center</i> , 2013, 8, 169-76.	0.3	21
148	Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2018, 13, 1-9.	0.7	21
149	Monoclonal Antibody a Promising Treatment for Depression. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 1-2.	0.3	21
150	Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 139-144.	1.5	20
151	A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. <i>Psychopharmacology</i> , 2012, 220, 591-598.	3.1	20
152	Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial. <i>Pharmacopsychiatry</i> , 2015, 48, 268-273.	3.3	20
153	Lipoid proteinosis: phenotypic heterogeneity in Iranian families with c.507delT mutation in <i>ECM1</i> . <i>Experimental Dermatology</i> , 2015, 24, 220-222.	2.9	20
154	A placebo controlled randomized clinical trial of <i>Crocus sativus</i> L. (saffron) on depression and food craving among overweight women with mild to moderate depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 134-143.	1.5	20
155	L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. <i>Psychiatry Research</i> , 2018, 262, 94-101.	3.3	19
156	Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence. <i>International Clinical Psychopharmacology</i> , 2018, 33, 111-119.	1.7	19
157	Setting research priorities to achieve long-term health targets in Iran. <i>Journal of Global Health</i> , 2018, 8, 020702.	2.7	19
158	Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 1407-1414.	4.0	19
159	Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1619-1628.	4.7	19
160	Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. <i>Journal of Psychopharmacology</i> , 2020, 34, 506-513.	4.0	19
161	A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. <i>Acta Medica Iranica</i> , 2015, 53, 337-45.	0.8	19
162	Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 133-138.	1.5	18

#	ARTICLE	IF	CITATIONS
163	Pharmacotherapy of Schizophrenia: The Past, Present and Future. <i>Current Drug Therapy</i> , 2006, 1, 1-7.	0.3	18
164	Infectious agents and different course of multiple sclerosis: a systematic review. <i>Acta Neurologica Belgica</i> , 2018, 118, 361-377.	1.1	18
165	Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. <i>Clinical Neuropharmacology</i> , 2020, 43, 39-45.	0.7	18
166	Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment. <i>Iranian Journal of Psychiatry</i> , 2018, 13, 46-54.	0.7	18
167	Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 846-855.	0.7	17
168	Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy. <i>Addiction</i> , 2017, 112, 415-429.	3.3	17
169	Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 82-89.	1.3	17
170	L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2020, 267, 131-136.	4.1	17
171	Cardiovascular effects of saffron: an evidence-based review. <i>Journal of Tehran University Heart Center</i> , 2011, 6, 59-61.	0.2	17
172	Research in Iran: An Overview. <i>Avicenna Journal of Medical Biotechnology</i> , 2017, 9, 1.	0.3	17
173	Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naïve patients with acute mania: a double blind and placebo controlled trial. <i>BMC Psychiatry</i> , 2003, 3, 7.	2.6	16
174	l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 331-338.	1.3	16
175	Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. <i>Swiss Medical Weekly</i> , 2014, 144, w13880.	1.6	16
176	Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 775-782.	2.1	16
177	Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement?. <i>Iranian Journal of Psychiatry</i> , 2012, 7, 114-9.	0.7	16
178	Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2016, 49, 162-169.	3.3	15
179	Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 250-255.	1.8	15
180	Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. <i>Acta Medica Iranica</i> , 2014, 52, 675-80.	0.8	15

#	ARTICLE	IF	CITATIONS
181	Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 379-384.	1.5	14
182	Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. <i>International Journal of Methods in Psychiatric Research</i> , 2019, 28, e1768.	2.1	14
183	The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110091.	4.8	14
184	Are Supplementation of Omega-3 and Ascorbic Acid Effective in Reducing Oxidative Stress and Depression among Depressed Shift Workers?. <i>International Journal for Vitamin and Nutrition Research</i> , 2015, 85, 299-310.	1.5	14
185	Efficacy and Safety of Oral Combination of Yohimbine and L-arginine (SX) for the Treatment of Erectile Dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial. <i>Iranian Journal of Psychiatry</i> , 2010, 5, 1-3.	0.7	14
186	Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia*. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 453-459.	1.5	13
187	Autism Spectrum Disorders: Etiology and Pharmacotherapy. <i>Current Drug Therapy</i> , 2007, 2, 97-103.	0.3	13
188	Herbal Medicines in the Treatment of Psychiatric and Neurological Disorders. , 2007, , 119-138.		13
189	Cyproheptadine for Prevention of Neuropsychiatric Adverse Effects of Efavirenz: A Randomized Clinical Trial. <i>AIDS Patient Care and STDs</i> , 2013, 27, 146-154.	2.5	13
190	Efficacy and safety of tifepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 690-696.	1.8	13
191	Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. <i>Child Psychiatry and Human Development</i> , 2021, 52, 928-938.	1.9	13
192	5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. <i>International Clinical Psychopharmacology</i> , 2020, 35, 254-262.	1.7	13
193	Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 804-811.	1.5	13
194	Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 280-304.	2.1	13
195	Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2017, 12, 154-162.	0.7	13
196	Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. <i>Acta Medica Iranica</i> , 2011, 49, 487-98.	0.8	13
197	Antidepressant-like effect of magnetic resonance imaging-based stimulation in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 503-509.	4.8	12
198	Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. <i>Human Psychopharmacology</i> , 2011, 26, 120-124.	1.5	12

#	ARTICLE	IF	CITATIONS
199	Efficacy of melatonin as an adjunct in the treatment of acute mania. <i>International Clinical Psychopharmacology</i> , 2020, 35, 81-88.	1.7	12
200	Contribution of health researches in national knowledge production: A scientometrics study on 15-year research products of Iran. <i>International Journal of Preventive Medicine</i> , 2017, 8, 27.	0.4	12
201	Topiramate prevents ecstasy consumption: a case report. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 601-602.	1.9	11
202	Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 305-315.	4.0	11
203	Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. <i>International Clinical Psychopharmacology</i> , 2021, 36, 140-146.	1.7	11
204	The Importance of Clinical Trials in Drug Development. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 151.	0.3	11
205	Comparing the Effects of High-Dose Vitamin E With Those of Placebo on Insulin Resistance in Patients With Schizophrenia Treated With Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 182-183.	1.4	10
206	Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2012, 20, 43.	2.0	10
207	Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. <i>Human Psychopharmacology</i> , 2017, 32, e2583.	1.5	10
208	Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Clinical Neuropharmacology</i> , 2019, 42, 189-196.	0.7	10
209	Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 169-174.	1.8	10
210	Personalized medicine: a tailor made medicine. <i>Avicenna Journal of Medical Biotechnology</i> , 2014, 6, 191.	0.3	10
211	Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2016, 5, 32-38.	0.2	10
212	Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. <i>Archives of Iranian Medicine</i> , 2006, 9, 374-80.	0.6	10
213	Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study. <i>Acta Medica Iranica</i> , 2012, 50, 723-8.	0.8	10
214	Medical Science and Research in Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, 665-672.	0.6	10
215	Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 505-511.	1.8	10
216	POTENTIATION OF MUSCIMOL-INDUCED LONG-TERM DEPRESSION BY BENZODIAZEPINES AND PREVENTION OR REVERSAL BY PREGNENOLONE SULFATE. <i>Pharmacological Research</i> , 1998, 38, 441-448.	7.1	9

#	ARTICLE	IF	CITATIONS
217	Total Antioxidant Capacity and Malondialdehyde in Depressive Rotational Shift Workers. <i>Journal of Environmental and Public Health</i> , 2013, 2013, 1-5.	0.9	9
218	Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial?. <i>Clinical Neuropharmacology</i> , 2020, 43, 139-145.	0.7	9
219	How the US Sanctions Are Affecting the Health Research System in Iran?. <i>Archives of Iranian Medicine</i> , 2021, 24, 101-106.	0.6	9
220	Prospects of Saffron and its Derivatives in Alzheimer's Disease. <i>Archives of Iranian Medicine</i> , 2021, 24, 233-252.	0.6	9
221	Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. <i>Iranian Journal of Psychiatry</i> , 2015, 10, 106-14.	0.7	9
222	New Hopes for Treatment of Alzheimer's Disease. <i>Avicenna Journal of Medical Biotechnology</i> , 2018, 10, 1.	0.3	9
223	Glutamate-independent long-term depression in rat hippocampus by activation of GABAA receptors. <i>Life Sciences</i> , 1996, 58, 1023-1030.	4.3	8
224	Sudden hearing loss subsequent to diarrhea: what is the missing link?. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 15.	2.0	8
225	Vitamin E and ginseng supplementation to enhance female sexual function: a randomized, double-blind, placebo-controlled, clinical trial. <i>Women and Health</i> , 2020, 60, 1164-1173.	1.0	8
226	Medical Biotechnology and Alzheimer's Disease: New Hopes. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 1.	0.3	8
227	Reliability and Validity of the Persian Version of Compulsive Eating Scale (CES) in Overweight or Obese Women and Its Relationship with Some Body Composition and Dietary Intake Variables. <i>Iranian Journal of Psychiatry</i> , 2016, 11, 250-256.	0.7	8
228	Major Depressive Disorder in Children and Adolescents After Renal Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1627-1629.	0.6	7
229	Citicoline (CDP-choline) addition therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: double-blind, randomized placebo-controlled trial. <i>Human Psychopharmacology</i> , 2018, 33, e2662.	1.5	7
230	Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 170-175.	1.7	7
231	Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 97-104.	1.5	7
232	Efficacy and safety of Sophora alopecuroides var. alopecuroides seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial. <i>Phytotherapy Research</i> , 2020, 34, 1108-1113.	5.8	7
233	Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychosomatic Research</i> , 2021, 150, 110635.	2.6	7
234	Oxidative Stress and Depression among Male Shift Workers in Shahid Tondgouyan Refinery. <i>Iranian Journal of Psychiatry</i> , 2014, 9, 76-82.	0.7	7

#	ARTICLE	IF	CITATIONS
235	Efficacy and safety of saffron as adjunctive therapy in adults with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Advances in Integrative Medicine</i> , 2022, 9, 37-43.	0.9	7
236	Research Ranking of Iranian Universities of Medical Sciences Based on International Indicators: An Experience From I.R. of Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, 673-679.	0.6	7
237	Diseases and Health Outcomes Registry Systems in I.R. Iran: Successful Initiative to Improve Public Health Programs, Quality of Care, and Biomedical Research. <i>Archives of Iranian Medicine</i> , 2017, 20, 696-703.	0.6	7
238	Trends of Mental Health Status in Iranian Population Aged 15 and above between 1999 and 2015. <i>Archives of Iranian Medicine</i> , 2017, 20, S2-S6.	0.6	7
239	Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. <i>International Clinical Psychopharmacology</i> , 2022, 37, 92-101.	1.7	7
240	Mental health study process into prevalence of mental disorders in Iran. <i>Archives of Iranian Medicine</i> , 2015, 18, 74-5.	0.6	7
241	Muscimol-induced long-term depression in the hippocampus: Lack of dependence on extracellular calcium. <i>Neuroscience</i> , 1996, 71, 581-588.	2.3	6
242	Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. <i>Journal of Psychiatric Research</i> , 2017, 94, 70-77.	3.1	6
243	Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial. <i>Advances in Integrative Medicine</i> , 2018, 5, 69-74.	0.9	6
244	Therapeutic effects of saffron (<i>Crocus sativus</i>) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial. <i>Advances in Integrative Medicine</i> , 2019, 6, 167-173.	0.9	6
245	Infectious Agents and Stroke: A Systematic Review. <i>Basic and Clinical Neuroscience</i> , 2021, 12, 427-440.	0.6	6
246	Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 155-159.	1.5	6
247	Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 609-614.	0.2	6
248	The efficacy of vitamin B6 as an adjunctive therapy to lithium in improving the symptoms of acute mania in patients with bipolar disorder, type 1; a double-blind, randomized, placebo-controlled, clinical trial. <i>Brain and Behavior</i> , 2021, 11, e2394.	2.2	6
249	Autistic disorders and medical biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2015, 7, 1.	0.3	6
250	Alzheimer's disease: pathophysiology and pharmacotherapy. <i>IDrugs: the Investigational Drugs Journal</i> , 2002, 5, 1062-9.	0.7	6
251	Potential by neurosteroids of muscimol/adenosine interactions in rat hippocampus. <i>Brain Research</i> , 1995, 677, 311-318.	2.2	5
252	Cyproheptadine in treatment of autism. <i>European Psychiatry</i> , 2002, 17, 230-231.	0.2	5

#	ARTICLE	IF	CITATIONS
253	Potential of muscimol-induced long-term depression by benzodiazepines but not zolpidem. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1161-1166.	4.8	5
254	Combination of citalopram and nortriptyline in the treatment of severe major depression: a double-blind, placebo-controlled trial. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 187-192.	0.2	5
255	A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 236-242.	1.4	5
256	Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial. <i>Psychopharmacology</i> , 2022, 239, 551-559.	3.1	5
257	Development of Health Research Structures Over the Last 25 Years: Main Achievements and Challenges. <i>Archives of Iranian Medicine</i> , 2017, 20, 659-664.	0.6	5
258	Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 745-751.	0.2	4
259	Autism Spectrum Disorders in Iran. , 0, , .		4
260	Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial. <i>Journal of Integrative Medicine</i> , 2020, 18, 409-415.	3.1	4
261	Vitamin E and ginseng combined supplement for treatment of male erectile dysfunction: A double-blind, placebo-controlled, randomized, clinical trial. <i>Advances in Integrative Medicine</i> , 2021, 8, 44-49.	0.9	4
262	Medicinal Plants in the Treatment of Obsessive-Compulsive Disorder: A Review. <i>Current Drug Discovery Technologies</i> , 2021, 18, 8-16.	1.2	4
263	Saffron () versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. <i>Avicenna Journal of Phytomedicine</i> , 2018, 8, 513-523.	0.2	4
264	How to Assess Quality of Research in Iran, From Input to Impact? Introduction of Peer-Based Research Evaluation Model in Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, 680-685.	0.6	4
265	The Role of Medical Research Centers in Health Research System Promotion in I.R. of Iran: 2001-2014. <i>Archives of Iranian Medicine</i> , 2016, 20, 686-690.	0.6	4
266	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Tehran, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S115-S118.	0.6	4
267	Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. <i>International Clinical Psychopharmacology</i> , 2022, 37, 46-53.	1.7	4
268	Maintenance of muscimol-induced long-term depression by neurosteroids. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1996, 20, 277-289.	4.8	3
269	Prevention of muscimol-induced long-term depression by brain-derived neurotrophic factor. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1999, 23, 1215-1226.	4.8	3
270	Celecoxib for schizophrenia. <i>The Cochrane Library</i> , 2011, , .	2.8	3

#	ARTICLE	IF	CITATIONS
271	Fluticasone propionate in clinically suspected asthma patients with negative methacholine challenge test. <i>Clinical Respiratory Journal</i> , 2017, 11, 433-439.	1.6	3
272	Possibility for science without borders in the Trump era. <i>Lancet, The</i> , 2019, 393, 405-406.	13.7	3
273	Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. <i>Advances in Integrative Medicine</i> , 2020, 7, 141-147.	0.9	3
274	Efficacy and safety of tipegidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 57-62.	1.8	3
275	Microbiome and Schizophrenia. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 269.	0.3	3
276	Is it time to have another look at lithium maintenance therapy in bipolar disorder?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1999, 23, 1011-1017.	4.8	2
277	Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Â. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 399-406.	0.2	2
278	More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia. <i>Evidence-Based Mental Health</i> , 2017, 20, e3-e3.	4.5	2
279	Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence. <i>Archives of Iranian Medicine</i> , 2021, 24, 409-418.	0.6	2
280	Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 799-807.	4.7	2
281	A Tool to Reduce the Problems of Iranian Health Researchers. <i>Iranian Journal of Public Health</i> , 2020, 49, 2441-2442.	0.5	2
282	Health Research Governance: Introduction of a New Web-based Research Evaluation Model in Iran: One-decade Experience. <i>Iranian Journal of Public Health</i> , 2016, 45, 1309-1314.	0.5	2
283	Depression and Inflammation: Is There any Role for Biomarkers?. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 207.	0.3	2
284	Protection against the Omicron and Subsequent Coronavirus Variants: Medical-grade Masking, Third Dose Vaccination, Updating Vaccines, and Pursuing Universal Vaccine. <i>Avicenna Journal of Medical Biotechnology</i> , 2022, 14, 1-2.	0.3	2
285	Oxcarbazepine versus sodium valproate in treatment of acute mania. <i>International Clinical Psychopharmacology</i> , 2022, Publish Ahead of Print, .	1.7	2
286	Possible effects of Saffron (<i>Crocus sativus</i>) in the treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled trial. <i>Journal of Herbal Medicine</i> , 2022, 32, 100551.	2.0	2
287	Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. <i>Acta Medica Iranica</i> , 2016, 54, 261-9.	0.8	2
288	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Ardebil, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S11-S14.	0.6	2

#	ARTICLE	IF	CITATIONS
289	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Chaharmahal and Bakhtiari, Iran. Archives of Iranian Medicine, 2017, 20, S19-S22.	0.6	2
290	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Markazi, Iran. Archives of Iranian Medicine, 2017, 20, S79-S82.	0.6	2
291	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Mazandaran, Iran. Archives of Iranian Medicine, 2017, 20, S83-S86.	0.6	2
292	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Razavi Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S99-S102.	0.6	2
293	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Semnan, Iran. Archives of Iranian Medicine, 2017, 20, S103-S106.	0.6	2
294	Efficacy of Spironolactone As an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia; A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. Iranian Journal of Psychiatry, 2022, 17, 14-23.	0.7	2
295	Expectations of Health Researchers From Academic Social Network Sites: Qualitative Study. Journal of Medical Internet Research, 2021, 23, e24643.	4.3	2
296	Hydroxyzine may be safe and effective in generalised anxiety disorder. Evidence-Based Mental Health, 2003, 6, 91-91.	4.5	1
297	Published research on attention deficit hyperactivity disorder : a comparative analysis of <scp>medline</scp> and an Iranian bibliographic database. Health Information and Libraries Journal, 2010, 27, 155-157.	2.5	1
298	Allopurinol and related drugs for schizophrenia. The Cochrane Library, 2012, , .	2.8	1
299	The effects of opium tincture and methadone on the cognitive function of patients with opioid use disorder. Personality and Individual Differences, 2021, 169, 110091.	2.9	1
300	Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry, 2021, 16, 52-59.	0.7	1
301	Efficacy and tolerability of Lavandula angustifolia in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. Journal of Complementary and Integrative Medicine, 2021, .	0.9	1
302	Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia?. Therapy: Open Access in Clinical Medicine, 2005, 2, 745-751.	0.2	1
303	The meeting of psychiatry and humanities: an overview. Journal of Medical Ethics and History of Medicine, 2009, 2, 5.	0.6	1
304	Microbiota and Autism Spectrum Disorder. Avicenna Journal of Medical Biotechnology, 2019, 11, 129.	0.3	1
305	Evaluation of Drug and Alcohol Abuse in People Aged 15 Years and Older in Iran. Iranian Journal of Public Health, 2020, 49, 1940-1946.	0.5	1
306	Basic Science and Clinical Studies on Non-COVID-19 Topics, of Coronavirus Victims. Avicenna Journal of Medical Biotechnology, 2021, 13, 1.	0.3	1

#	ARTICLE	IF	CITATIONS
307	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of East Azarbaijan, Iran. Archives of Iranian Medicine, 2017, 20, S23-S26.	0.6	1
308	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Fars, Iran. Archives of Iranian Medicine, 2017, 20, S27-S30.	0.6	1
309	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Hamadan, Iran. Archives of Iranian Medicine, 2017, 20, S39-S42.	0.6	1
310	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kermanshah, Iran. Archives of Iranian Medicine, 2017, 20, S59-S62.	0.6	1
311	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Khouzestan, Iran. Archives of Iranian Medicine, 2017, 20, S63-S66.	0.6	1
312	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kordestan, Iran. Archives of Iranian Medicine, 2017, 20, S71-S74.	0.6	1
313	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Lorestan, Iran. Archives of Iranian Medicine, 2017, 20, S75-S78.	0.6	1
314	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Sistan and Bluchestan, Iran. Archives of Iranian Medicine, 2017, 20, S107-S110.	0.6	1
315	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of West Azarbaijan, Iran. Archives of Iranian Medicine, 2017, 20, S119-S122.	0.6	1
316	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Yazd, Iran. Archives of Iranian Medicine, 2017, 20, S123-S126.	0.6	1
317	Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran. Drug and Alcohol Review, 2022, 41, 895-901.	2.1	1
318	Author's response to Yang R <i>et al</i> .: Several concerns arise when the results are interpreted. Human Psychopharmacology, 2011, 26, 88-88.	1.5	0
319	Author's Reply to the Letter to the Editor by Fountoulakis. Pharmacopsychiatry, 2018, 51, 106-107.	3.3	0
320	Application of saffron as a neuroprotective agent. , 2020, , 445-450.		0
321	The Requisiteness for not Sacrificing Medical Biotechnology in the Coronavirus Era. Avicenna Journal of Medical Biotechnology, 2021, 13, 53.	0.3	0
322	Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial. IJC Heart and Vasculature, 2021, 34, 100789.	1.1	0
323	Medical Biotechnology in the Service of Coronavirus Vaccine Discovery and Production. Avicenna Journal of Medical Biotechnology, 2021, 13, 105-106.	0.3	0
324	The Necessity of Preserving the Research System in Emergency Eras. Archives of Iranian Medicine, 2021, 24, 583-584.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 399-406.	0.2	0
326	Allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 739-744.	0.2	0
327	Personality Patterns in Narcotics Anonymous Members versus Individuals with Addiction Receiving Methadone Maintenance Therapy. <i>Iranian Journal of Psychiatry</i> , 2014, 9, 158-62.	0.7	0
328	Evidence Based Medicine and Medical Biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2015, 7, 133.	0.3	0
329	The Economic Aspects of Medical Biotechnology. <i>Avicenna Journal of Medical Biotechnology</i> , 2016, 8, 1.	0.3	0
330	Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia. <i>Avicenna Journal of Medical Biotechnology</i> , 2018, 10, 125.	0.3	0
331	Development of Evaluation System for Iranian Health Research Networks: Challenges and Lessons Learned. <i>Iranian Journal of Public Health</i> , 2020, 49, 104-113.	0.5	0
332	Repositioning Drugs for Psychiatry. <i>Avicenna Journal of Medical Biotechnology</i> , 2020, 12, 67.	0.3	0
333	Knowledge production in Iranian cardiovascular research centers: A way to reduce the burden of disease. <i>ARYA Atherosclerosis</i> , 2020, 16, 72-78.	0.4	0
334	Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 137.	0.9	0
335	Basic Science and Clinical Studies on Non-COVID-19 Topics, of Coronavirus Victims. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 1.	0.3	0
336	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Alborz, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S7-S10.	0.6	0
337	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Bushehr, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S15-S18.	0.6	0
338	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Gilan, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S31-S34.	0.6	0
339	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Golestan, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S35-S38.	0.6	0
340	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Hormozgan, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S43-S46.	0.6	0
341	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Ilam, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S47-S50.	0.6	0
342	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Isfahan, Iran. <i>Archives of Iranian Medicine</i> , 2017, 20, S51-S54.	0.6	0

#	ARTICLE	IF	CITATIONS
343	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kerman, Iran. Archives of Iranian Medicine, 2017, 20, S55-S58.	0.6	0
344	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Kohgiluyeh and Bouyerahmad, Iran. Archives of Iranian Medicine, 2017, 20, S67-S70.	0.6	0
345	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of North Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S87-S90.	0.6	0
346	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Qazvin, Iran. Archives of Iranian Medicine, 2017, 20, S91-S94.	0.6	0
347	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Qom, Iran. Archives of Iranian Medicine, 2017, 20, S95-S98.	0.6	0
348	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of South Khorasan, Iran. Archives of Iranian Medicine, 2017, 20, S111-S114.	0.6	0
349	A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Zanjan, Iran. Archives of Iranian Medicine, 2017, 20, S127-S130.	0.6	0
350	Establishment of the National Network of WHO Collaborating Centres in Iran to Contribute to the National Public Health Needs. Archives of Iranian Medicine, 2015, 18, 558-9.	0.6	0
351	Integrating Psychiatry and Medical Biotechnology as a Way to Achieve Scientific, Precision, and Personalized Psychiatry.. Avicenna Journal of Medical Biotechnology, 2021, 13, 172-175.	0.3	0
352	Melatonin Effects in Women With Comorbidities of Overweight, Depression, and Sleep Disturbance: A Randomized Placebo Controlled Clinical Trial. Sleep Medicine Research, 0, , .	0.6	0
353	Professor Moslem Bahadori (1927â€“2022), a Matchless Role Model in Modern Academic Medicine in Iran. Archives of Iranian Medicine, 2022, 25, 347-352.	0.6	0